Summary
We studied the effects of entacapone, a novel inhibitor of the enzyme catechol-O-methyltransferase (COMT), on spontaneous and levodopa (LD) modulated secretion of growth hormone (GH) and prolactin (PRL) in 12 healthy male volunteers. The study had a double-blind, crossover design with two experimental settings. In the first setting the subjects received a single oral dose of 400 mg of entacapone or matching placebo in a randomized order. In the second setting, a single oral dose of 300 mg of LD and 75 mg of carbidopa was administered concomitantly with either 400 mg of entacapone or matching placebo in a randomized order. Entacapone had no effect on resting levels of GH, but PRL concentrations in plasma were slightly lower after entacapone than after placebo. As expected, LD/carbidopa increased the concentration of GH and decreased that of PRL. The effects of LD were not influenced by concomitant administration of entacapone. Compared with the administration of LD/carbidopa together with placebo, concomitant administration of entacapone increased the AUC of LD by 29% and reduced the AUC of 3-O-methyldopa (a metabolite of LD produced by COMT) by 69%. Entacapone appears not to enhance the effects of LD on hypothalamic-pituitary function, although the LD dose used may have been bigger than optimal for detection of a small modulatory influence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bäckström R, Honkanen E, Pippuri A, et al (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J Med Chem 32: 841–846
Brown GM, Garfinkel PE, Warsh JJ, Stancer HC (1976) Effect of carbidopa on prolactin, growth hormone and cortisol secretion in man. J Clin Endocrinol Metab 43: 236–239
Camanni F, Massara F, Belforte L, et al (1977) Effects of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects. J Clin Endocrinol Metab 44: 465–473
Eddy RL, Jones AL, Chakmakjian ZH, Silverthorne MC (1971) Effect of levodopa (L-dopa) on human hypophyseal trophic hormone release. J Clin Endocrinol Metab 33: 709–712
Eisler T, Thorner MO, MacLeod RM, et al (1981) Prolactin secretion in Parkinson's disease. Neurology 31: 1356–1359
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd ed. Dekker, New York
Kaakkola S, Wurtman RJ (1992) Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res 587: 241–249
Kaakkola S, Gordin A, Männistö PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 25: 813–824
Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 77–80
Keränen T, Gordin A, Harjola VP, et al (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145–156
Keränen T, Gordin A, Karlsson M, et al (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46: 151–157
Koulu M, Lammintausta R (1981) Effects of L-Deprenyl on human growth hormone secretion. J Neural Transm 51: 223–231
Kytömäki O, Nousiainen R, Pekkarinen A, Rinne UK, Viljanen M (1973) Plasma growth hormone and insulin response to levodopa and amantadine. J Neural Transm 34: 145–151
Mars H, Genuth SM (1973) Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition. Clin Pharmacol Ther 14: 390–395
Masturzo P, De Maria A, Murialdo G, et al (1985) Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic men. J Clin Endocrinol Metab 61: 378–381
Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57: 186–189
Nissinen E, Lindén IB, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346: 262–266
Nutt JG, Woodward WR, Beckner RM, et al (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913–919
Polleri A, Masturzo P, Murialdo G, Carolei A (1980) Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans. Acta Endocrinol 93: 7–12
Ritschel WA (1986) Handbook of basic pharmacokinetics, 3rd ed. Drug Intelligence Publications, Illinois
Ruggieri S, Falaschi P, Baldassarre M, et al (1982) Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. Neuropsychobiology 8: 102–108
Sundberg S, Scheinin M, Illi A, et al (1993) The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 36: 451–456
Wikberg T (1991) Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 9: 167–176
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Keränen, T., Gordin, A., Koulu, M. et al. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. J. Neural Transmission 103, 729–736 (1996). https://doi.org/10.1007/BF01271232
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01271232